While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

Nvidia (NVDA, Financials) said Tuesday it is partnering with Novo Nordisk to accelerate drug discovery using its generative ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Eli Lilly already has a couple of top GLP-1 drugs that help patients with diabetes (Mounjaro) and weight loss (Zepbound), but ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

No, Donald Trump was not the focus of attention this week, even though the US president invited people to a parade to ...

Recursion Pharmaceuticals ( RXRX -5.13%) is not the most famous artificial intelligence (AI) stock on the market, but the ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...